journal article·2022-12-28

Enhancement in Site-Specific Delivery of Chloramphenicol Using Bacterially Sensitive Microparticle Loaded Into Dissolving Microneedle: Potential For Enhanced Effectiveness Treatment of Cellulitis

Mukarram Mudjahid, Firzan Nainu, Rifka Nurul Utami, Anwar Sam, Ardiyah Nurul Fitri Marzaman, Tri Puspita Roska, Rangga Meidianto Asri, Achmad Himawan, Ryan F. Donnelly, Andi Dian Permana

ACS Applied Materials & Interfaces· Volume 14· Issue 51
Publisher page

Abstract

One of the biggest challenges in infectious disease treatment is the existence of bacterial infections in underskin wound tissue, such as cellulitis. Compared to other treatments, it is harder for antibacterial drugs to penetrate the physical barrier on the affected skin with a nonspecific target, making conventional therapy for cellulitis infection more difficult and considered. In this novel research, we pioneer a combined strategy of dissolving microneedles (MNs) and bacteria-sensitive microparticles (MPs) for enhanced penetration and targeted delivery of chloramphenicol (CHL) to the infection site specifically. The polycaprolactone polymer was used to make MPs because of its sensitivity to bacterial enzyme stimuli. The best microparticle formulation was discovered and optimized using the Design–Expert application. Furthermore, this study evaluated the antibacterial activity of MPs in vitro and in vivo on the mutant Drosophila larval infection model. This strategy shows improvement in the antibacterial activity of MPs and higher retention duration compared to conventional cream formulation, and the inclusion of these MPs into dissolving MNs was able to greatly improve the dermatokinetic characteristics of CHL in ex vivo evaluation. Importantly, the antimicrobial efficacy in an ex vivo infection model demonstrated that, following the use of this strategy, bacterial bioburdens decreased by up to 99.99% after 24 h. The findings offered a proof of concept for the enhancement of CHL dermatokinetic profiles and antimicrobial activities after its preparation into bacteria-sensitive MPs and distribution by MNs. Future research should investigate in vivo effectiveness in an appropriate animal model.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Bee Products Chemical Analysis · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Faculty of Pharmacy, Hasanuddin University, Makassar90245, Indonesia

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Hasanuddin, Makassar90245, Indonesia

School of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, BelfastBT9 7BL, United Kingdom

Funding

Deutscher Akademischer Austauschdienst · Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi

References (58)

Show source-provided references
1. 10.1309/LMBNSWKUI4JPN7SO10.1309/LMBNSWKUI4JPN7SO ↗
2. 10.1111/iwj.1217210.1111/iwj.12172 ↗
3. 10.1016/j.msec.2017.02.00110.1016/j.msec.2017.02.001 ↗
4. 10.1001/jama.2016.882510.1001/jama.2016.8825 ↗
5. 10.1016/j.mcna.2021.04.00910.1016/j.mcna.2021.04.009 ↗
6. 10.1111/iwj.1369610.1111/iwj.13696 ↗
7. 10.1016/j.msec.2019.11013010.1016/j.msec.2019.110130 ↗
8. 10.3390/ijms1904117910.3390/ijms19041179 ↗
9. 10.1080/09205063.2020.181766710.1080/09205063.2020.1817667 ↗
10. 10.3390/pathogens1002024510.3390/pathogens10020245 ↗
11. 10.2147/IJN.S7502310.2147/IJN.S75023 ↗
12. 10.1016/B978-0-12-386454-3.00709-010.1016/B978-0-12-386454-3.00709-0 ↗
13. Shukla P. · J. Med. Med. Sci. · 2011 · 2 · 1313
14. 10.1126/science.109583310.1126/science.1095833 ↗
15. 10.3390/molecules2414254710.3390/molecules24142547 ↗
16. 10.1016/j.apsusc.2020.14680610.1016/j.apsusc.2020.146806 ↗
17. 10.1021/ja211279u10.1021/ja211279u ↗
18. 10.2147/IJN.S8410810.2147/IJN.S84108 ↗
19. 10.1002/wnan.169010.1002/wnan.1690 ↗
20. 10.1016/j.msec.2020.11178610.1016/j.msec.2020.111786 ↗
21. 10.3390/scipharm8703002010.3390/scipharm87030020 ↗
22. 10.2147/IJN.S7502310.2147/IJN.S75023 ↗
23. 10.3390/pharmaceutics1107034610.3390/pharmaceutics11070346 ↗
24. 10.1016/j.biopha.2017.07.01910.1016/j.biopha.2017.07.019 ↗
25. 10.1016/j.jconrel.2019.10.00410.1016/j.jconrel.2019.10.004 ↗
26. 10.1016/j.biopha.2018.07.10210.1016/j.biopha.2018.07.102 ↗
27. 10.1016/j.vaccine.2005.06.01610.1016/j.vaccine.2005.06.016 ↗
28. 10.1016/j.bjm.2015.10.00110.1016/j.bjm.2015.10.001 ↗
29. 10.2147/IDR.S17597810.2147/IDR.S175978 ↗
30. 10.1128/mBio.00276-2110.1128/mBio.00276-21 ↗
31. 10.1016/j.cmpb.2010.01.00710.1016/j.cmpb.2010.01.007 ↗
32. 10.1007/s12247-021-09593-y10.1007/s12247-021-09593-y ↗
33. 10.1016/j.ejpb.2020.06.02510.1016/j.ejpb.2020.06.025 ↗
34. 10.1016/j.jconrel.2017.07.03210.1016/j.jconrel.2017.07.032 ↗
35. 10.1007/s11095-015-1782-310.1007/s11095-015-1782-3 ↗
36. 10.1111/iwj.1308010.1111/iwj.13080 ↗
37. 10.1186/s11671-017-2249-810.1186/s11671-017-2249-8 ↗
38. 10.1016/j.jhazmat.2005.03.04210.1016/j.jhazmat.2005.03.042 ↗
39. 10.1016/j.ijpharm.2006.11.06110.1016/j.ijpharm.2006.11.061 ↗
40. 10.3109/10717544.2012.65771810.3109/10717544.2012.657718 ↗
41. 10.2147/IJN.S6873710.2147/IJN.S68737 ↗
42. 10.1007/s10934-020-00981-210.1007/s10934-020-00981-2 ↗
43. 10.1007/s11051-019-4617-z10.1007/s11051-019-4617-z ↗
44. 10.1186/s40064-015-1476-710.1186/s40064-015-1476-7 ↗
45. 10.1016/j.carbpol.2010.10.02210.1016/j.carbpol.2010.10.022 ↗
46. 10.1039/C8NR07146B10.1039/C8NR07146B ↗
47. 10.1016/S0032-3861(99)00586-810.1016/S0032-3861(99)00586-8 ↗
48. 10.1016/j.jconrel.2020.09.02010.1016/j.jconrel.2020.09.020 ↗
49. Clinical and Laboratory Standards Institute (CLSI) · 2012
50. 10.1016/j.diagmicrobio.2013.11.01010.1016/j.diagmicrobio.2013.11.010 ↗
51. 10.1038/nri376310.1038/nri3763 ↗
52. 10.4308/hjb.27.4.30610.4308/hjb.27.4.306 ↗
53. 10.1038/ni.164310.1038/ni.1643 ↗
54. 10.1073/pnas.090192410610.1073/pnas.0901924106 ↗
55. 10.1016/j.ijpharm.2014.05.04210.1016/j.ijpharm.2014.05.042 ↗
56. 10.1016/j.ejps.2018.05.00910.1016/j.ejps.2018.05.009 ↗
57. 10.1016/j.ijpx.2020.10004710.1016/j.ijpx.2020.100047 ↗
58. 10.3390/pharmaceutics1111060610.3390/pharmaceutics11110606 ↗